Fateme Babaha: Pleasure to Present A Novel FVIII Gene Therapy Enhancer at ISTH 2026
Fateme Babaha, PhD in Pathology and Molecular Medicine at Queen’s University, shared on LinkedIn:
”It was a pleasure to present my research at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris!
It had the opportunity to present my work, ‘Efficacy of AAV-mediated FVIII transgene expression employing a short enhancer element from the human F8 locus,’ and to connect with researchers and experts in the field of hemophilia and gene therapy.
In this study, we investigated a novel, compact 92-bp enhancer element from the human F8 locus and its potential to improve FVIII transgene expression for hemophilia A gene therapy.
I’m grateful to my supervisor Dr. David Lillicrap for his continued support and to everyone who stopped by my poster for the insightful discussions and questions.”
Stay updated with Hemostasis Today.
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH
-
Sep 9, 2026, 16:07Zahra Safarzadeh: From Novel F8 Variant to Clinical Significance
-
Sep 9, 2026, 16:00Maximo Agustin Schiavone: HDL Beyond Cholesterol – Linking Lipids and Immunity
-
Sep 9, 2026, 15:56Abdul Mannan: When Antiseizure Drugs Alter DOAC Risk